HCV Synthesis Project: Preliminary analyses of HCV prevalence in relation to age and duration of injection

International Journal of Drug Policy

Volumn 18, Issue 5, 2007, Pages 341-351

  Hagan, Holly ^a   Des Jarlais, Don C ^a,b   Stern, Rebecca ^a   Lelutiu Weinberger, Corina ^a   Scheinmann, Roberta ^a   Strauss, Shiela ^a   Flom, Peter L ^a  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Epidemiology; Hepatitis C; Injection drug use; Meta analysis; Prevention; Youth

Indexed keywords

DATA ANALYSIS; DISEASE DURATION; DRUG DEPENDENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; ONSET AGE; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICAL ANALYSIS; VIRUS TRANSMISSION;

ADULT; AGE FACTORS; EPIDEMIOLOGIC METHODS; FEMALE; HARM REDUCTION; HEALTH EDUCATION; HEPATITIS C; HUMANS; MALE; NATIONAL HEALTH PROGRAMS; PREVALENCE; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 34548480460     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2007.01.016     Document Type: Review

References (100)

1. Aarons E., Grant P., Soldan K., Luton P., Tang J., and Tedder R. Failure to diagnose recent hepatitis C virus infections in London injecting drug users. Journal of Medical Virology 73 4 (2004) 548-553
2. Abdala N., Carney J.M., Durante A.J., Klimov N., Ostrovski D., Somlai A.M., et al. Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St. Petersburg, Russia. International Journal of STD & AIDS 14 10 (2003) 697-703
3. Alizadeh A.H., Alavian S.M., Jafari K., and Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan-Iran. World Journal of Gastroenterology 11 26 (2005) 4085-4089
4. Allwright S., Bradley F., Long J., Barry J., Thornton L., and Parry J.V. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: Results of a national cross sectional survey. British Medical Journal 321 7253 (2000) 78-82
5. Anand C.M., Fonseca K., Walle R.P., Powell S., and Williams M. Antibody to hepatitis C virus in selected groups of a Canadian urban population. International Journal of Epidemiology 21 1 (1992) 142-145
6. Bair R.M., Baillargeon J.G., Kelly P.J., Lerand S.J., Williams J.F., Lyerla R., et al. Prevalence and risk factors for hepatitis C virus infection among adolescents in detention. Archives of Pediatrics & Adolescent Medicine 159 11 (2005) 1015-1018
7. Balogun M.A., Ramsay M.E., Parry J.V., Donovan L., Andrews N.J., Newham J.A., et al. A national survey of genitourinary medicine clinic attenders provides little evidence of sexual transmission of hepatitis C virus infection. Sexually Transmitted Infections 79 4 (2003) 301-306
8. Bell J., Batey R.G., Farrell G.C., Crewe E.B., Cunningham A.L., and Byth K. Hepatitis C virus in intravenous drug users. The Medical Journal of Australia 153 5 (1990) 274-276
9. Bolumar F., Hernandez-Aguado I., Ferrer L., Ruiz I., Avino M.J., and Rebagliato M. Prevalence of antibiotics to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990-1992. International Journal of Epidemiology 25 1 (1996) 204-209
10. Butler T., Spencer J., Cui J., Vickery K., Zou J., and Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners-NSW, 1996. Australian and New Zealand Journal of Public Health 23 4 (1999) 377-384
11. Cao K., Mizokami M., Orito E., Ding X., Ge X.M., Huang G.Y., et al. TT virus infection among IVDUs in south western China. Scandinavian Journal of Infectious Disease 31 1 (1999) 21-25
12. Chang C.J., Lin C.H., Lee C.T., Chang S.J., Ko Y.C., and Liu H.W. Hepatitis C virus infection among short-term intravenous drug users in southern Taiwan. European Journal of Epidemiology 15 7 (1999) 597-601
13. Christensen P.B., Krarup H.B., Niesters H.G., Norder H., and Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. European Journal of Epidemiology 16 11 (2000) 1043-1049
14. Coppola R.C., Masia G., di Martino M.L., Carboni G., Muggianu E., Piro R., et al. Sexual behaviour and multiple infections in drug abusers. European Journal of Epidemiology 12 5 (1996) 429-435
15. Craine N., Walker A.M., Williamson S., Brown A., and Hope V.D. Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Communicable Disease and Public Health 7 3 (2004) 216-219
16. Crofts N., Hopper J.L., Bowden D.S., Breschkin A.M., Milner R., and Locarnini S.A. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Medical Journal of Australia 159 4 (1993) 237-241
17. Crofts N., Jolley D., Kaldor J., van Beek I., and Wodak A. The epidemiology of HCV infection among injecting drug users in Australia. The Journal of Epidemiology and Community Health 51 6 (1997) 692-697
18. Crofts N., Stewart T., Hearne P., Ping X.Y., Breshkin A.M., and Locarnini S.A. Spread of bloodborne viruses among Australian prison entrants. British Medical Journal 310 6975 (1995) 285-288
19. de Carvalho H.B., Mesquita F., Massad E., Bueno R.C., Lopes G.T., Ruiz M.A., et al. HIV and infections of similar transmission patterns in a drug injectors community of Santos, Brazil. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 12 1 (1996) 84-92
20. Des Jarlais D.C., Perlis T., Arasteh K., Torian L.V., Hagan H., Beatrice S., et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 19 Suppl 3 (2005) 20-25
21. Denis B., Dedobbeleer M., Collet T., Petit J., Jamoulle M., Hayani A., et al. High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the "cotton-filter" in transmission: The GEMT Study. Acta Gastro-Enterologica Belgica 63 2 (2000) 147-153
22. Diaz T., Des Jarlais D.C., Vlahov D., Perlis T.E., Edwards V., Friedman, et al. Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York City. American Journal of Public Health 91 1 (2001) 23-30
23. Eicher A.D., Crofts N., Benjamin S., Deutschmann P., and Rodger A.J. A certain fate: Spread of HIV among young injecting drug users in Manipur, north-east India. AIDS Care 12 4 (2000) 497-504
24. Esteban J.I., Esteban R., Viladomiu L., Lopez-Talavera J.C., Gonzalez A., Hernandez J.M., et al. Hepatitis C virus antibodies among risk groups in Spain. The Lancet 2 8658 (1989) 294-297
25. Fingerhood M.I., Jasinski D.R., and Sullivan J.T. Prevalence of hepatitis C in a chemically dependent population. Archives of Internal Medicine 153 17 (1993) 2025-2030
26. Garfein R.S., Doherty M.C., Monterroso E.R., Thomas D.L., Nelson K.E., and Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18 Suppl 1 (1998) S11-S19
27. Garfein R.S., Vlahov D., Galai N., Doherty M.C., and Nelson K.E. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health 86 5 (1996) 655-671
28. Garten R.J.L.S., Zhang J., Liu W., Chen J., Vlahov D., and Yu X.F. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. International Journal of Epidemiology 33 1 (2003) 1-7
29. Gerberding J.L. Management of occupational exposures to blood-borne viruses. The New England Journal of Medicine 332 7 (1995) 444-451
30. Gil A.R., Navarro H.I., Casanovas E.A., Rubio S.G., and Dols T.S. Risk behaviours and seroprevalence to HIV, HBV and HCV in patients of the AIDS information and prevention center in Valencia, Spain. Gaceta Sanitaria 13 1 (1999) 16-21
31. Goldberg D., Burns S., Taylor A., Cameron S., Hargreaves D., and Hutchinson S. Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. Scandinavian Journal of Infectious Diseases 33 6 (2001) 457-461
32. Goldberg D., Cameron S., and McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Communicable Disease and Public Health 1 2 (1998) 95-97
33. Gombas W., Fischer G., Jagsch R., Eder H., Okamoto I., Schindler S., et al. Prevalence and distribution of hepatitis C subtypes in patients with opioid dependence. European Addiction Research 6 4 (2000) 198-204
34. Gyarmathy V.A., Neaigus A., Miller M., Friedman S.R., and Des Jarlais D.C. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 30 4 (2002) 448-456
35. Hagan H., Campbell J., Thiede H., Strathdee S., Ouellet L., Kapadia F., et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports 121 6 (November-December 2006)
36. Hagan, H., Campbell, J., Thiede, H., Strathdee, S., Ouellet, L., Latka, M., et al. (submitted for publication). Injecting alone among young IDUs in five U.S. cities: Evidence of low rates of injection risk behavior. Drug and Alcohol Dependence.
37. Hagan H., and Des Jarlais D.C. HIV and HCV infection among injecting drug users. Mount Sinai Journal of Medicine 67 5 & 6 (2000) 423-428
38. Hagan H., Thiede H., and Des Jarlais D.C. Hepatitis C virus infection among injection drug users: Survival analysis of time to seroconversion. Epidemiology 15 5 (2004) 543-549
39. Hagan H., Thiede H., Weiss N.S., Hopkins S.G., Duchin J.S., and Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 91 1 (2001) 42-46
40. Hahn J.A., Page-Shafer K., Lum P.J., Bourgois P., Stein E., Evans J.L., et al. Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. Journal of Infectious Diseases 186 11 (2002) 1558-1564
41. Hahn J.A., Page-Shafer K., Lum P.J., Ochoa K., and Moss A.R. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 34 1 (2001) 180-187
42. Haydon G.H., Flegg P.J., Blair C.S., Brettle R.P., Burns S.M., and Hayes P.C. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. European Journal of Gastroenterology and Hepatology 10 6 (1998) 485-489
43. Hernandez-Aguado I., et al. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. European Journal of Epidemiology 17 6 (2001) 539-544
44. In: Heymann D.L. (Ed). Control Of Communicable Diseases Manual (18th edition) (2004), American Public Health Association, Washington, DC
45. Hocking J., Crofts N., Aitken C., and MacDonald M. Epidemiology of the hepatitis C virus among injecting drug users. In: Crofts N., Dore G., and Locarnini S. (Eds). Hepatitis C: An Australian perspective (2001), IP Communications, Victoria, Australia 260-295
46. Hope V.D., Judd A., Hickman M., Lamagni T., Hunter G., Stimson G.V., et al. Prevalence of hepatitis C among injection drug users in England and Wales: Is harm reduction working?. American Journal of Public Health 91 1 (2001) 38-42
47. Judd A., Hutchinson S., Wadd S., Hickman M., Taylor A., Jones S., et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: Cross sectional analysis. Journal of Viral Hepatitis 12 6 (2005) 655-662
48. Kelen G.D., Green G.B., Purcell R.H., Chan D.W., Qaqish B.F., Sivertson K.T., et al. Hepatitis B and hepatitis C in emergency department patients. New England Journal of Medicine 326 21 (1992) 1399-1404
49. Kemp R., Miller J., Lungley S., and Baker M. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations. The New Zealand Medical Journal 111 1060 (1998) 50-53
50. Kennedy N., Tong C.Y., Beeching N.J., Lamden K., Williams H., Mutton K.J., et al. Hepatitis G virus infection in drug users in Liverpool. Journal of Infection 37 2 (1998) 140-147
51. Kwiatkowski C.F., Corsi K.F., and Booth R.E. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 97 10 (2002) 1289-1294
52. Lai S., Liu W., Chen J., Yang J., Li Z.J., Li R.J., et al. Changes in HIV-1 incidence in heroin users in Guangxi Province, China. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 26 4 (2001) 365-370
53. Laskus T., Radkowski M., Lupa E., Slusarczyk J., Cianciara J., Halama G., et al. Prevalence of markers of hepatotropic viruses among drug addicts in Warsaw, Poland. Journal of Hepatology 15 1-2 (1992) 114-117
54. Latt N.C., Spencer J.D., Beeby P.J., McCaughan G.W., Saunders J.B., Collins E., et al. Hepatitis C in injecting drug-using women during and after pregnancy. Journal of Gastroenterology and Hepatology 15 2 (2000) 175-181
55. Long J., Allwright S., Barry J., Reynolds S.R., Thornton L., Bradley F., et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: A national cross sectional survey. British Medical Journal 323 7323 (2001) 1209-1213
56. Love A., and Stanzeit B. Hepatitis C virus infection in Iceland: A recently introduced blood-borne disease. Epidemiology and Infection 113 3 (1994) 529-536
57. Lucidarme D., Bruandet A., Ilef D., Harbonnier J., Jacob C., Decoster A., et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiology and Infection 132 4 (2004) 699-708
58. MacDonald M.A., Wodak A.D., Dolan K.A., van Beek I., Cunningham P.H., and Kaldor J.M. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programmes in Australia, 1995-1997. Collaboration of Australian NSPs. Medical Journal of Australia 172 2 (2000) 57-61
59. Maher L., Chant K., Jalaludin B., and Sargent P. Risk behaviours and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. Journal of Gastroenterology and Hepatology 19 10 (2004) 1114-1120
60. Maher L., Jalaludin B., Chant K.G., Jayasuriya R., Sladden T.K., Kaldor J.M., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 101 10 (2006) 1499-1508
61. Mathei C., Robaeys G., van Damme P., Buntinx F., and Verrando R. Prevalence of hepatitis C in drug users in Flanders: Determinants and geographic differences. Epidemiology and Infection 133 1 (2005) 127-136
62. McCoy C.B., Metsch L.R., Collado-Mesa F., Arheart K.L., Messiah S.E., Katz D., et al. The prevalence of human immunodeficiency virus type 1 and hepatitis C virus among injection drug users who use high risk inner-city locales in Miami, Florida. Memorias de Instituto Oswaldo Cruz 99 8 (2004) 789-793
63. McIntyre P.G., Hill D.A., Appleyard K., Taylor A., Hutchinson S., and Goldberg D.J. Prevalence of antibodies to hepatitis C virus, HIV and human T-cell leukemia/lymphoma viruses in injecting drug users in Tayside, Scotland, 1993-1997. Epidemiology and Infection 126 1 (2001) 97-101
64. McMahon J.M., and Tortu S. A potential hidden source of hepatitis C infection among non-injecting drug users. Journal of Psychoactive Drugs 35 4 (2003) 455-460
65. Miller C.L., Johnston C., Spittal P.M., Li K., LaLiberte N., Montaner J.S.G., et al. Opportunities for Prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 36 3 (2002) 737-742
66. Montella M., Crispo A., Grimaldi M., Angeletti C., Amore A., Ronga D., et al. Prevalence of hepatitis C virus infection in different population groups in southern Italy. Infection 33 1 (2005) 9-12
67. Murrill C.S., Weeks H., Castrucci B.C., Weinstock H.S., Bell B.P., Spruill C., et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. American Journal of Public Health 92 3 (2002) 385-387
68. Nanping W., Li D., Zhu B., and Zou W. Preliminary research on the co-infection of human immunodeficiency virus and hepatitis virus in intravenous drug users. Chinese Medical Journal (England) 116 9 (2003) 1318-1320
69. Ompad D.C., Fuller C.M., Vlahov D., Thomas D., and Strathdee S.A. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clinical Infectious Diseases 35 (2002) 783-788
70. Patrick D.M., Tyndall M.W., Cornelisse P.G.A., Li K., Sherlock C.H., Rekart M.L., et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canadian Medical Association Journal 165 7 (2001) 889-895
71. Patti A.M., Santi A.L., Pompa M.G., Giustini C., Vescia N., Mastroeni I., et al. Viral hepatitis and drugs: A continuing problem. International Journal of Epidemiology 22 1 (1993) 135-139
72. Rhodes T., Kimber J., Small W., Fitzgerald J., Kerr T., Hickman M., et al. Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction 101 10 (2006) 1384-1393
73. Rhodes T., Platt L., Sarang A., Vlasov A., Mikailova L., and Monaghan G. Street policing, injecting drug use and harm reduction in a Russian city: A qualitative study of police perspectives. Journal of Urban Health 83 5 (2006) 911-925
74. Robinson G.M., Reynolds J.N., and Robinson B.J. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users. The New Zealand Medical Journal 108 996 (1995) 103-105
75. Roy K., Hay G., Andragetti R., Taylor A., Goldberg D., and Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: A review of the literature. Epidemiology and Infection 129 3 (2002) 577-585
76. Ruan Y.H., Hong K.X., Liu S.Z., He Y.X., Zhou F., Qin G.M., et al. Community-based survey of HCV and HIV coinfection in injection drug abusers in Sichuan Province of China. World Journal of Gastroenterology 10 11 (2004) 1589-1593
77. Scheinmann R., Hagan H., Lelutiu-Weinberger C., Stern R., Des Jarlais D.C., Flom P.L., et al. Non-injection drug use and hepatitis C: A systematic review. Drug and Alcohol Dependence (2006) (Dec 14 [Epub ahead of print])
78. Shirin T., Ahmed T., Iqbal A., Islam M., and Islam M.N. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. Journal of Health, Population, and Nutrition 18 3 (2000) 145-150
79. Siragusa R., Passarino G., Mollo F., and Tappero P. HCV positivity at postmortem among 793 heroin addicts examined in Piedmont (Italy). Panminerva Medica 43 2 (2001) 119-121
80. Smyth B.P., Barry J., and Keenan E. Irish injecting drug users and hepatitis C: The importance of the social context of injecting. International Journal of Epidemiology 34 1 (2005) 166-172
81. Smyth B.P., Keenan E., and O'Connor J.J. Bloodborne viral infection in Irish injecting drug users. Addiction 93 11 (1998) 1649-1656
82. Smyth B.P., Keenan E., and O'Connor J.J. Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users. Journal of Epidemiology and Community Health 53 7 (1999) 434-435
83. Smyth B.P., O'Connor J.J., Barry J., and Keenan E. Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin. Journal of Epidemiology and Community Health 57 4 (2003) 310-311
84. Stark K., Muller R., Bienzle U., and Guggenmoos-Holzmann I. Frontloading: A risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS 10 3 (1996) 311-317
85. Stark K., Schreier E., Muller R., Wirth D., Driesel G., and Bienzle U. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scandinavian Journal of Infectious Diseases 27 4 (1995) 331-337
86. Steffen T., Blattler R., Gutzwiller F., and Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. European Journal of Public Health 11 4 (2001) 425-430
87. Thomas D.L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R., et al. Correlates of hepatitis C virus infections among injection drug users. Medicine 74 4 (1995) 212-220
88. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology 155 7 (2002) 645-653
89. Thorpe L.E., Ouellet L.J., Levy J.R., Williams I.T., and Monterroso E.R. Hepatitis C virus infection: Prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. Journal of Infectious Diseases 182 6 (2000) 1588-1594
90. Tor J., Llibre J.M., Carbonell M., Muga R., Ribera A., Soriano V., et al. Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. British Medical Journal 301 6761 (1990) 1130-1133
91. Tortu S., Neaigus A., McMahon J., and Hagen D. Hepatitis C among noninjecting drug users: A report. Substance Use and Misuse 36 4 (2001) 523-534
92. Trisler Z., Seme K., Poljak M., Celan-Lucu B., and Sakoman S. Prevalence of hepatitis C and G virus infections among intravenous drug users in Slovenia and Croatia. Scandinavian Journal of Infectious Diseases 31 1 (1999) 33-35
93. van Ameijden E.J., van den Hoek J.A., Mientjes G.H., and Coutinho R.A. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. European Journal of Epidemiology 9 3 (1993) 255-262
94. van Beek I., Buckley R., Stewart M., MacDonald M., and Kaldor J. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourinary Medicine 70 5 (1994) 321-324
95. van Beek I., Dwyer R., Dore G.J., Luo K., and Kaldor J.M. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study. British Medical Journal 317 7156 (1998) 433-437
96. van de Laar T.J., Langendam M.W., Bruisten S.M., Welp E.A., Verhaest I., van Ameijden E.J., et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, The Netherlands. Journal of Medical Virology 77 4 (2005) 509-518
97. van den Hoek J.A., van Haastrecht H.J., Goudsmit J., de Wolf F., and Coutinho R.A. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. Journal of Infectious Diseases 162 4 (1990) 823-826
98. Wasley A., and Alter M.J. Epidemiology of hepatitis C: Geographic differences and temporal trends. Seminars in Liver Disease 20 1 (2000) 1-16
99. Weissenbacher M., Rossi D., Radulich G., Sosa-Estani S., Vila M., Vivas E., et al. High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clinical Infectious Diseases 37 Suppl 5 (2003) S348-S352
100. Williams P.G., Ansell S.M., and Milne F.J. Illicit intravenous drug use in Johannesburg-Medical complications and prevalence of HIV infection. South African Medical Journal 87 7 (1997) 889-891